Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer
1996

Trial of Isotretinoin and Calcitriol in Ovarian Cancer

Sample size: 22 publication Evidence: low

Author Information

Author(s): GJS Rustin, TG Quinnell, J Johnson, H Clarke, AE Nelstrop, W Bollag

Primary Institution: Mount Vernon Centre for Cancer Treatment

Hypothesis

Can isotretinoin combined with calcitriol effectively treat ovarian cancer as monitored by CA 125 levels?

Conclusion

The combination of isotretinoin and calcitriol did not show any significant treatment effect in patients with ovarian cancer.

Supporting Evidence

  • Sixteen patients received at least 9 weeks of treatment but showed no significant response according to CA 125 criteria.
  • Clinical evidence of tumor progression was observed in 11 of 17 evaluable patients.
  • Only one patient showed a potential benefit from the treatment, suggesting a longer period without progression.

Takeaway

Doctors tested two medicines to see if they could help women with ovarian cancer, but they found that the medicines didn't work.

Methodology

Patients with rising CA 125 levels after chemotherapy were treated with isotretinoin and calcitriol, and their tumor response was monitored through CA 125 levels.

Limitations

The study had a small sample size and lacked significant responses in the majority of patients.

Participant Demographics

All participants were women with a diagnosis of epithelial ovarian carcinoma who had previously undergone chemotherapy.

Statistical Information

P-Value

0.45

Statistical Significance

p = 0.45

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication